Singapore: Janssen Pharmaceutical has terminated the research and development alliance with China based Hutchison Medipharma (HMP) related to small molecule, HMPL-507 for inflammation.

The almost seven year alliance, which began in 2008, was amended in 2010 to refocus the target of the research on developing small molecule therapeutics against a specific novel molecular target in the area of inflammation/immunology.

During this time, Janssen paid HMP an aggregate of approximately USD13 million in upfront and milestone payments and service fees and costs, which enabled both parties to generate substantial intellectual property, understanding and know-how relating to compounds in this designated area.

Janssen, at its sole discretion, has decided not to proceed with either HMPL-507 or any of the backup compounds developed under the agreement.

HMP and Janssen will continue to work together on projects in other contexts.